209 related articles for article (PubMed ID: 29408205)
21. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.
Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
Genet Med; 2018 Sep; 20(9):1087-1090. PubMed ID: 29215650
[TBL] [Abstract][Full Text] [Related]
22. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
[TBL] [Abstract][Full Text] [Related]
23. Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families.
Liang X; Pfeiffer RM; Li WQ; Brossard M; Burke LS; Wheeler W; Calista D; Fargnoli MC; Ghiorzo P; Peris K; Bianchi-Scarra G; Chaudru V; Zelenika D; Maeder D; Burdette L; Yeager M; Chanock S; Landi MT; Demenais F; Tucker MA; Goldstein AM; Yang XR
J Invest Dermatol; 2014 Feb; 134(2):481-487. PubMed ID: 23892592
[TBL] [Abstract][Full Text] [Related]
24. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.
Sargen MR; Pfeiffer RM; Yang XR; Tucker MA; Goldstein AM
J Invest Dermatol; 2020 Jan; 140(1):174-181.e3. PubMed ID: 31326397
[TBL] [Abstract][Full Text] [Related]
25. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families.
Goldstein AM; Martinez M; Tucker MA; Demenais F
Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):889-94. PubMed ID: 11008905
[TBL] [Abstract][Full Text] [Related]
26. CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross-sectional descriptive trial.
Arnaut JRMB; Guimarães IDS; Dos Santos ACE; Rodrigues EM; Machado JRDS; de Melo AC
Int J Dermatol; 2023 Aug; 62(8):1060-1066. PubMed ID: 37322831
[TBL] [Abstract][Full Text] [Related]
27. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LA; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; ;
J Med Genet; 2007 Feb; 44(2):99-106. PubMed ID: 16905682
[TBL] [Abstract][Full Text] [Related]
28. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management.
Slade J; Marghoob AA; Salopek TG; Rigel DS; Kopf AW; Bart RS
J Am Acad Dermatol; 1995 Mar; 32(3):479-94. PubMed ID: 7868720
[TBL] [Abstract][Full Text] [Related]
29. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
30. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
[TBL] [Abstract][Full Text] [Related]
31. Population-based prevalence of CDKN2A mutations in Utah melanoma families.
Eliason MJ; Larson AA; Florell SR; Zone JJ; Cannon-Albright LA; Samlowski WE; Leachman SA
J Invest Dermatol; 2006 Mar; 126(3):660-6. PubMed ID: 16397522
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic carcinoma surveillance in patients with familial melanoma.
Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
[TBL] [Abstract][Full Text] [Related]
33. Cancer risks in BRCA2 mutation carriers.
Breast Cancer Linkage Consortium
J Natl Cancer Inst; 1999 Aug; 91(15):1310-6. PubMed ID: 10433620
[TBL] [Abstract][Full Text] [Related]
34. Risk of melanoma and other cancers in melanoma-prone families.
Tucker MA; Fraser MC; Goldstein AM; Elder DE; Guerry D; Organic SM
J Invest Dermatol; 1993 Mar; 100(3):350S-355S. PubMed ID: 8440923
[TBL] [Abstract][Full Text] [Related]
35. The genetics of hereditary melanoma and nevi. 1998 update.
Greene MH
Cancer; 1999 Dec; 86(11 Suppl):2464-77. PubMed ID: 10630172
[TBL] [Abstract][Full Text] [Related]
36. Familial cutaneous melanoma.
Lucchina LC; Barnhill RL; Duke DM; Sober AJ
Melanoma Res; 1995 Dec; 5(6):413-8. PubMed ID: 8589615
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
[TBL] [Abstract][Full Text] [Related]
38. Multiple primary melanomas: analysis of 49 cases.
Savoia P; Quaglino P; Verrone A; Bernengo MG
Melanoma Res; 1998 Aug; 8(4):361-6. PubMed ID: 9764812
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
[TBL] [Abstract][Full Text] [Related]
40. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
